Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120748 | 1.00 | MMP2 (0.56) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL28736783 | 0.98 | MMP2 (0.55) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| Trifluoroacetic Acid SCHEMBL3587833 | 0.91 | MMP2 (0.52) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL9275540 | 0.90 | MMP2 (0.64) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL8526418 | 0.90 | MMP2 (0.64) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL3907033 | 0.89 | MMP2 (0.71) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL8691002 | 0.89 | MMP2 (0.71) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL5555507 | 0.87 | SLC1A1 (0.57) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL18952189 | 0.87 | SPHK1 (0.62) | MMP2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL29968173 | 0.87 | TPSAB1 (0.56) | MMP2CYP1A2CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
| US-6740657-B2 | FOR EXAMPLE, N3-CYCLOPROPYL-7-((2,6-DICHLOROPHENYL)METHYL)-9-((DIMETHYLAMINO)METHYL)-7H -PYRROLO(3,2-F) QUINAZOLINE-1,3-DIAMI NE; TREATING CARDIOVASCULAR DISORDERS, RESTENOSIS, THROMBOSIS, AND OTHER DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-05-25 | — | — | US | disclosed |
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160963-A1 | Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists | F2R, F2RL1, F2RL3 | MMP2 962/4885CYP1A2 2290/4885CYP2D6 3522/4885 |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | MMP2 3375/4885CYP1A2 3738/4885CYP2D6 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.